Market Cap (In SEK)
1.62 Billion
Revenue (In SEK)
130 Thousand
Net Income (In SEK)
-151.85 Million
Avg. Volume
346.22 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 6.41-25.0
- PE
- -
- EPS
- -
- Beta Value
- 2.139
- ISIN
- SE0005162880
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Ulf Hannelius MBA, Ph.D.
- Employee Count
- -
- Website
- https://www.diamyd.com
- Ipo Date
- 2013-05-20
- Details
- Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase IIb clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is in phase I/II clinical trial for the treatment of autoimmune and type 2 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was incorporated in 1984 and is based in Stockholm, Sweden.
More Stocks
-
CNQQFClean TeQ Water Limited
CNQQF
-
SPELS
-
RATHF
-
8112
-
EKPElkop SE
EKP
-
CETI
-
601200
-
1918